Holen Sie sich die Stockscreener-App
22.98
3.36%
-0.80
Schlusskurs vom Vortag:
$23.78
Offen:
$23.29
24-Stunden-Volumen:
695.96K
Relative Volume:
0.86
Marktkapitalisierung:
$1.39B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-7.5357
EPS:
-3.0495
Netto-Cashflow:
$-154.68M
1W Leistung:
-6.74%
1M Leistung:
+44.62%
6M Leistung:
+52.08%
1J Leistung:
-34.59%
1-Tages-Spanne:
$22.87
$23.56
1-Wochen-Bereich:
$22.42
$25.00
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
22.98 | 1.84B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Will Spyre Therapeutics Inc. (3920) stock see insider accumulation2025 Investor Takeaways & Safe Capital Growth Plans - newser.com
Why Spyre Therapeutics Inc. stock is seen as undervaluedWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Is Spyre Therapeutics Inc. stock a buy for dividend growthPortfolio Update Report & Free Daily Entry Point Trade Alerts - newser.com
Using Ichimoku Cloud for Spyre Therapeutics Inc. technicalsJuly 2025 Intraday Action & Precise Entry and Exit Recommendations - newser.com
Is a relief rally coming for Spyre Therapeutics Inc. holders2025 Price Action Summary & AI Based Trade Execution Alerts - newser.com
What margin trends mean for Spyre Therapeutics Inc. stock2025 Trading Recap & Daily Growth Stock Tips - newser.com
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus
Spyre Therapeutics Reports Q3 2025 Financial Results - TipRanks
Spyre Therapeutics: Q3 Earnings Snapshot - Chron
Spyre (SYRE) Enhances Position with Positive Phase 1 Data and St - GuruFocus
Spyre Therapeutics reports positive interim data for IBD drug SPY003 - Investing.com
Spyre Therapeutics Reports Positive Phase 1 Results for SPY003 - TipRanks
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - The Manila Times
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Stock Titan
Will Spyre Therapeutics Inc. stock maintain dividend yield2025 Historical Comparison & Weekly Top Gainers Trade List - newser.com
Will Spyre Therapeutics Inc. stock recover faster than peers2025 Retail Activity & Stock Market Timing Techniques - newser.com
Published on: 2025-11-04 03:55:19 - newser.com
Can a trend reversal in Spyre Therapeutics Inc. lead to recoveryTrade Exit Report & Consistent Profit Alerts - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientEarnings Trend Report & Verified Technical Trade Signals - newser.com
Using data tools to time your Spyre Therapeutics Inc. exitPortfolio Profit Report & Precise Swing Trade Alerts - newser.com
Will Spyre Therapeutics Inc. stock sustain high P E ratios2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulationWeekly Investment Recap & Advanced Technical Signal Analysis - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stockJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
Backtesting results for Spyre Therapeutics Inc. trading strategies2025 EndofYear Setup & Risk Managed Investment Signals - newser.com
Why retail investors favor Spyre Therapeutics Inc. stock2025 Bull vs Bear & AI Powered Market Trend Analysis - newser.com
What insider purchases suggest about Spyre Therapeutics Inc. (3920) stockMarket Movers & AI Driven Stock Reports - newser.com
What dividend safety score for Spyre Therapeutics Inc. stockChart Signals & Free Accurate Trade Setup Notifications - newser.com
Can Spyre Therapeutics Inc. stock sustain free cash flow growthShare Buyback & AI Powered Market Entry Strategies - newser.com
Will Spyre Therapeutics Inc. (3920) stock beat international competitionMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Will Spyre Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Highlights & Smart Swing Trading Alerts - newser.com
Will Spyre Therapeutics Inc. (3920) stock sustain uptrend momentumStop Loss & Expert Verified Movement Alerts - newser.com
Is Spyre Therapeutics Inc. (3920) stock undervalued after correction2025 Price Momentum & Consistent Growth Stock Picks - newser.com
Is Spyre Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Why Spyre Therapeutics Inc. stock remains on watchlistsPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
How to escape a deep drawdown in Spyre Therapeutics Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
Published on: 2025-11-02 03:35:20 - newser.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):